医学
慢性阻塞性肺病
他汀类
内科学
危险系数
队列
比例危险模型
人口
队列研究
药方
药品
死因
置信区间
疾病
药理学
环境卫生
作者
Adam Raymakers,Mohsen Sadatsafavi,Don D. Sin,Mary A. De Vera,Larry D. Lynd
出处
期刊:Chest
[Elsevier BV]
日期:2017-02-13
卷期号:152 (3): 486-493
被引量:47
标识
DOI:10.1016/j.chest.2017.02.002
摘要
Background
Patients with COPD are often prescribed statin drugs due to the increased prevalence of cardiovascular disease. There is considerable debate about the benefits conferred by statin drugs in patients with COPD. This study evaluates the association of statin drug use with all-cause and lung-related mortality in patients with COPD. Methods
This study uses population-based administrative data for the province of British Columbia, Canada. A cohort of patients with COPD was identified based on individual patient prescription records. Statin drug exposure was ascertained in the 1-year period after the COPD diagnosis. The primary and secondary outcomes, all-cause and lung-related mortality, respectively, were evaluated in the 1-year period thereafter using multivariate Cox proportional hazards models and several definitions of medication exposure. Results
There were 39,678 patients with COPD that met the study inclusion criteria. Of them, 7,775 (19.6%) had received at least one statin drug dispensed in the exposure ascertainment window. There were 1,446 all-cause deaths recorded in the cohort in the 1-year period after exposure ascertainment. In multivariate analysis, the estimated hazard ratio (HR) for statin drug exposure was 0.79 (95% CI, 0.68-0.92; P = .0016), suggesting a 21% reduction in the risk from statin drug use on all-cause mortality. For lung-related mortality, there was also a considerable reduction in the risk for all-cause mortality from statin drug use (HR, 0.55; 95% CI, 0.32-0.93; P = .0254). These results were robust to different specifications of the exposure ascertainment window. Conclusions
This study shows that statin drug use in a population-based cohort of patients with COPD may confer benefits regarding reduced lung-related and all-cause mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI